Zhang Xueying, Zhang Xiaohong, Lei Mingming, Lin Yingzi, Megson Ian L, Wei Jun, Yu Bo, Jin Yuanzhe
Department of Cardiovascular Medicine, The First Affiliated Hospital of China Medical University, Shenyang 110001, China ; Department of Cardiovascular Medicine, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China.
Department of Cardiovascular Medicine, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China.
FEBS Open Bio. 2015 Aug 11;5:712-6. doi: 10.1016/j.fob.2015.08.006. eCollection 2015.
A number of studies have reported an association between increased levels of antibodies against oxidized low-density lipoprotein (oxLDL) and cardiovascular disease, but the anti-oxLDL antibody has not been confirmed to serve as an effective biomarker for prediction of acute myocardial infarction (AMI). Apolipoprotein B100 (ApoB100)-derived peptide fragments generated by proteolytic degradation and aldehyde modification are the major antigens in oxLDL, and so the present work was undertaken to detect circulating IgG for Apo-B100-derived peptide antigens. An in-house enzyme-linked immunosorbent assay (ELISA) was developed with eight ApoB100-derived peptide antigens (Ag1-Ag8) to detect circulating anti-ApoB100 IgG levels in 267 patients with AMI and 201 control subjects. Binary logistic regression analysis revealed that circulating IgG for Ag1 was significantly higher in the patient group than the control group (P < 0.001) after adjustment for age, gender, smoking, hypertension, diabetes and circulating levels of cholesterol, HDL, LDL, ApoA and ApoB100. None of the other seven antigens detected an increase in IgG levels in AMI patients compared with control subjects. Spearman correlation analysis showed no correlation between IgG antibody for Ag1 and clinical characteristics. In conclusion, the linear peptide antigens derived from ApoB100 may be suitable for the development of an ELISA antibody test for prediction of AMI, although further confirmation is still needed in large-scale clinical studies.
多项研究报告了氧化型低密度脂蛋白（oxLDL）抗体水平升高与心血管疾病之间的关联，但抗oxLDL抗体尚未被确认为预测急性心肌梗死（AMI）的有效生物标志物。蛋白水解降解和醛修饰产生的载脂蛋白B100（ApoB100）衍生肽片段是oxLDL中的主要抗原，因此开展本研究以检测Apo-B100衍生肽抗原的循环IgG。利用8种ApoB100衍生肽抗原（Ag1-Ag8）开发了一种内部酶联免疫吸附测定（ELISA），以检测267例AMI患者和201例对照受试者的循环抗ApoB100 IgG水平。二元逻辑回归分析显示，在调整年龄、性别、吸烟、高血压、糖尿病以及胆固醇、高密度脂蛋白（HDL）、低密度脂蛋白（LDL）、载脂蛋白A（ApoA）和ApoB100的循环水平后，患者组中Ag1的循环IgG显著高于对照组（P < 0.001）。与对照受试者相比，其他七种抗原均未检测到AMI患者IgG水平升高。Spearman相关性分析显示，Ag1的IgG抗体与临床特征之间无相关性。总之，源自ApoB100的线性肽抗原可能适用于开发用于预测AMI的ELISA抗体检测，尽管仍需要大规模临床研究进行进一步证实。
